1. Home
  2. TBPH vs AXGN Comparison

TBPH vs AXGN Comparison

Compare TBPH & AXGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • AXGN
  • Stock Information
  • Founded
  • TBPH 2013
  • AXGN N/A
  • Country
  • TBPH United States
  • AXGN United States
  • Employees
  • TBPH N/A
  • AXGN N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • AXGN Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • TBPH Health Care
  • AXGN Health Care
  • Exchange
  • TBPH Nasdaq
  • AXGN Nasdaq
  • Market Cap
  • TBPH 536.5M
  • AXGN 517.4M
  • IPO Year
  • TBPH N/A
  • AXGN N/A
  • Fundamental
  • Price
  • TBPH $10.90
  • AXGN $12.67
  • Analyst Decision
  • TBPH Strong Buy
  • AXGN Strong Buy
  • Analyst Count
  • TBPH 5
  • AXGN 5
  • Target Price
  • TBPH $16.60
  • AXGN $26.00
  • AVG Volume (30 Days)
  • TBPH 158.6K
  • AXGN 1.4M
  • Earning Date
  • TBPH 08-12-2025
  • AXGN 08-05-2025
  • Dividend Yield
  • TBPH N/A
  • AXGN N/A
  • EPS Growth
  • TBPH N/A
  • AXGN N/A
  • EPS
  • TBPH N/A
  • AXGN N/A
  • Revenue
  • TBPH $65,266,000.00
  • AXGN $194,520,000.00
  • Revenue This Year
  • TBPH $51.74
  • AXGN $17.86
  • Revenue Next Year
  • TBPH N/A
  • AXGN $16.27
  • P/E Ratio
  • TBPH N/A
  • AXGN N/A
  • Revenue Growth
  • TBPH 6.11
  • AXGN 18.81
  • 52 Week Low
  • TBPH $7.44
  • AXGN $7.34
  • 52 Week High
  • TBPH $11.88
  • AXGN $21.00
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 45.21
  • AXGN 55.84
  • Support Level
  • TBPH $10.90
  • AXGN $12.99
  • Resistance Level
  • TBPH $11.26
  • AXGN $13.90
  • Average True Range (ATR)
  • TBPH 0.24
  • AXGN 0.79
  • MACD
  • TBPH -0.08
  • AXGN 0.06
  • Stochastic Oscillator
  • TBPH 2.00
  • AXGN 45.22

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About AXGN Axogen Inc.

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Share on Social Networks: